Carey K. Anders, MD, Duke Cancer Institute

Articles by Carey K. Anders, MD, Duke Cancer Institute

Dr. Anders on the Lessons Learned From the OlympiA Trial in BRCA-Mutated Breast Cancer

ByCarey K. Anders, MD, Duke Cancer Institute

January 11th 2022

Carey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Dr. Anders on Leveraging ADCs in Metastatic TNBC

ByCarey K. Anders, MD, Duke Cancer Institute

December 8th 2021

Carey K. Anders, MD, discusses leveraging antibody-drug conjugates in the treatment of patients with metastatic triple-negative breast cancer.

Impact of Recent Clinical Data on Treatment for HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2CLIMB: Brain Metastases Data

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Guidelines and Approaches to HER2 Testing for Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases

ByCarey K. Anders, MD, Duke Cancer Institute,Sarah L. Sammons, MD

June 5th 2020

Collectively, there are more options than ever in the space of HER2-positive breast cancer brain metastases, a significant advance for our hundreds and thousands of patients facing this challenging disease.

Latest Updated Articles

TRAIN-2: Anthracyclines in HER2+ Breast Cancer
Published: June 30th 2020 | Updated:
Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer
Published: June 30th 2020 | Updated:
Guidelines and Approaches to HER2 Testing for Breast Cancer
Published: June 30th 2020 | Updated:
HER2CLIMB: Brain Metastases Data
Published: June 30th 2020 | Updated:
Treatment Choice for Patient Relapsing With Brain Metastases
Published: June 30th 2020 | Updated:
HER2+ Early Stage Breast Cancer With Residual Invasive Disease
Published: June 30th 2020 | Updated:

Carey K. Anders, MD, Duke Cancer Institute

Articles by Carey K. Anders, MD, Duke Cancer Institute

Dr. Anders on the Lessons Learned From the OlympiA Trial in BRCA-Mutated Breast Cancer

Dr. Anders on Leveraging ADCs in Metastatic TNBC

Impact of Recent Clinical Data on Treatment for HER2+ MBC

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

Treatment Choice for Patient Relapsing With Brain Metastases

HER2CLIMB: Brain Metastases Data

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

HER2+ Early-Stage Breast Cancer

Guidelines and Approaches to HER2 Testing for Breast Cancer

Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases

Latest Updated Articles

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL